Based on the available evidence regarding the role of IL17 in psoriasis and PSA, four therapeutic agents against IL-17A, IL17F or its receptor have been developed: secukinumab, ixekizumab, brodalumab, and bimekizumab. The gene discussed is IL17A; the disease is psoriasis.